Table 1.
Demographic and baseline characteristics
| Brinzolamide/timolol (n = 58) | Dorzolamide/timolol (n = 57) | P-value | |
|---|---|---|---|
| Age, years | 0.5818a | ||
| Mean (standard deviation) | 64.2 (13.6) | 65.7 (15.7) | |
| Range (minimum, maximum) | (22, 85) | (19, 89) | |
| Sex, n (%) | 0.2159b | ||
| Men | 17 (29.3) | 24 (42.1) | |
| Women | 41 (70.7) | 33 (57.9) | |
| Race, n (%) | >0.999c | ||
| White | 46 (79.3) | 46 (80.7) | |
| Hispanic | 10 (17.2) | 10 (17.5) | |
| Black | 1 (1.7) | 1 (1.8) | |
| Asian | 1 (1.7) | 0 (0.0) | |
| Glaucoma diagnosis, n (%) | 0.7167c | ||
| Ocular hypertension | 3 (5.2) | 4 (7.0) | |
| Primary open-angle glaucoma | 55 (94.8) | 53 (93.0) | |
| Intraocular pressure, mmHg | 0.3706a | ||
| Mean (standard deviation) | 15.9 (3.3) | 15.6 (2.5) | |
| Range (minimum, maximum) | (9–27) | (8–22) |
Notes: Treatment groups were based on the randomization assignment for day 1, or the per-protocol population.
a
P-value calculated from a t-test;
b
P-value calculated from a Chi-square test;
c
P-value calculated from a Fisher’s exact test.